Literature DB >> 34784604

Clinical Utility of the Electrocardiographic P-Wave Axis in Patients with Chronic Obstructive Pulmonary Disease.

Shiro Otake1, Shotaro Chubachi1, Shingo Nakayama1, Kaori Sakurai1, Hidehiro Irie1, Mizuha Hashiguchi2, Yuji Itabashi3, Yoshitake Yamada4, Masahiro Jinzaki4, Mitsuru Murata3, Hidetoshi Nakamura5, Koichiro Asano6, Koichi Fukunaga1.   

Abstract

BACKGROUND: The vertical P-wave axis on electrocardiography (ECG) is a useful criterion for screening patients with chronic obstructive pulmonary disease (COPD). This study aimed to investigate the clinical characteristics of patients with COPD with a vertical P-wave axis as they have not yet been elucidated.
METHODS: Keio University and its affiliated hospitals conducted an observational COPD cohort study over 3 years. We analyzed 201 patients using ECG and chest computed tomography.
RESULTS: The severity of airflow limitation was higher in patients with a P-wave axis >75° than in those with a P-wave axis ≤75°. Patients with a P-wave axis >75° exhibited significantly higher total COPD assessment test scores and increased St. George's Respiratory Questionnaire total, activity, and impact scores than those with a P-wave axis ≤75°. The incidence of exacerbations over 1 and 3 years was significantly higher in patients with a P-wave axis >75° than in those with a P-wave axis ≤75°. The optimal cutoff for the P-wave axis for a percentage of the predicted forced expiratory volume in 1 s <50% and future exacerbations over 3 years was 70° (the areas under the curve [AUC]: 0.788; sensitivity: 65.3%; specificity: 78.3%) and 79° (AUC: 0.642; sensitivity: 36.7%; specificity: 92.6%). The ratio of the low attenuation area was also significantly higher in patients with a P-wave axis >75° than in those with a P-wave axis ≤75°. However, the ratio of the airway wall area did not differ between the 2 groups.
CONCLUSIONS: Patients with COPD with a vertical P-wave axis exhibited severe airflow limitation and emphysema, a worse health status, and more frequent exacerbation than patients without a vertical P-wave. Detection of the vertical P-wave axis by ECG is beneficial for the management of patients with COPD.
© 2021 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Chronic obstructive pulmonary disease; Electrocardiography; Emphysema; P-wave axis; QRS-wave axis

Mesh:

Year:  2021        PMID: 34784604      PMCID: PMC9153333          DOI: 10.1159/000519668

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.966


  38 in total

Review 1.  Health status measurement in chronic obstructive pulmonary disease.

Authors:  P W Jones
Journal:  Thorax       Date:  2001-11       Impact factor: 9.139

2.  Electrocardiographic screening for emphysema: the frontal plane P axis.

Authors:  R Baljepally; D H Spodick
Journal:  Clin Cardiol       Date:  1999-03       Impact factor: 2.882

3.  Electrocardiographic detection of emphysema.

Authors:  Anish J Thomas; Sirin Apiyasawat; David H Spodick
Journal:  Am J Cardiol       Date:  2011-04-01       Impact factor: 2.778

4.  Diaphragm levels as determinants of P axis in restrictive vs obstructive pulmonary disease.

Authors:  N S Shah; S M Koller; M L Janower; D H Spodick
Journal:  Chest       Date:  1995-03       Impact factor: 9.410

5.  Validity of the COPD assessment test translated into local languages for Asian patients.

Authors:  Namhee Kwon; Muhammad Amin; David S Hui; Ki-Suck Jung; Seong Yong Lim; Huu Duy Ta; Thi Thuy Linh Thai; Faisal Yunus; Paul W Jones
Journal:  Chest       Date:  2013-03       Impact factor: 9.410

6.  Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort.

Authors:  D A Lomas; E K Silverman; L D Edwards; B E Miller; H O Coxson; R Tal-Singer
Journal:  Thorax       Date:  2008-08-29       Impact factor: 9.139

7.  Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes.

Authors:  Meilan K Han; Ella A Kazerooni; David A Lynch; Lyrica X Liu; Susan Murray; Jeffrey L Curtis; Gerard J Criner; Victor Kim; Russell P Bowler; Nicola A Hanania; Antonio R Anzueto; Barry J Make; John E Hokanson; James D Crapo; Edwin K Silverman; Fernando J Martinez; George R Washko
Journal:  Radiology       Date:  2011-07-25       Impact factor: 11.105

8.  Analysis of comorbid factors that increase the COPD assessment test scores.

Authors:  Masaki Miyazaki; Hidetoshi Nakamura; Shotaro Chubachi; Mamoru Sasaki; Mizuha Haraguchi; Shuichi Yoshida; Keishi Tsuduki; Toru Shirahata; Saeko Takahashi; Naoto Minematsu; Hidefumi Koh; Morio Nakamura; Fumio Sakamaki; Takeshi Terashima; Koichi Sayama; Paul W Jones; Koichiro Asano; Tomoko Betsuyaku
Journal:  Respir Res       Date:  2014-02-06

9.  Impact of mild exacerbation on COPD symptoms in a Japanese cohort.

Authors:  Minako Sato; Shotaro Chubachi; Mamoru Sasaki; Mizuha Haraguchi; Naofumi Kameyama; Akihiro Tsutsumi; Saeko Takahashi; Hidetoshi Nakamura; Koichiro Asano; Tomoko Betsuyaku
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-06-09

10.  Clinical utility of blood neutrophil-lymphocyte ratio in Japanese COPD patients.

Authors:  Kaori Sakurai; Shotaro Chubachi; Hidehiro Irie; Akihiro Tsutsumi; Naofumi Kameyama; Takashi Kamatani; Hidefumi Koh; Takeshi Terashima; Hidetoshi Nakamura; Koichiro Asano; Tomoko Betsuyaku
Journal:  BMC Pulm Med       Date:  2018-05-02       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.